In fact, the only Hh pathway inhibitors clinically approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are SMO inhibitors: Vismodegib (GDC-0449, Erivedge®, Genentech, San Francisco, CA, USA) and Sonidegib (LDE225, Odomzo®, Sun Pharmaceutical Industries, Mumbai, India), for the treatment of adult BCC [80,81] and Glasdegib (PF-04449913, Daurismo®, Pfizer, New York, USA), employed in the treatment of newly-diagnosed acute myeloid leukaemia (AML) [82]. Here, SMO is linked to acute myeloid leukemia.